Sun Pharma Advanced Research Company Ltd

NSE: SPARC BSE: 532872

₹204.22

(0.83%)

Sat, 13 Jun 2026, 02:08 pm

MTF 5xInvest in Sun Pharma Advanced Research Company Ltd with 5x Leverage Buy with MTF

Market Cap (in Cr)6678.65

PE Ratio4.27

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Sun Pharma Advanced Research Company Ratios

D/E EV EV/EBITDA P/B P/CF P/E P/S ROE %

Particulars	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Price to earnings ratio	0	0	0	0	0	0	113.91	0	0	0	0	0	0	0	0	0	0	0
Price to book ratio	38.86	30.51	146.12	265.18	0	24.82	24.77	116.67	227.92	49.44	51.40	16.98	0	0	258.46	11.36	95.47	0
Price to sales ratio	44.71	30.97	60.02	25.56	53.36	28.39	20.66	74.76	42.26	43.07	119.94	26.84	32.92	14.68	56.91	21.40	158.92	66.92
Price to cash flow ratio	0	43.05	164.25	538.66	0	0	114.37	0	0	0	0	0	0	0	0	0	0	0
Enterprise value	1675Cr	1090Cr	2062Cr	1493Cr	1608Cr	2455Cr	3443Cr	11629Cr	6858Cr	7719Cr	9280Cr	4698Cr	2588Cr	3934Cr	7878Cr	4722Cr	11910Cr	5070Cr
Enterprise value to EBITDA ratio	81.59	0	0	0	0	0	101.89	0	0	0	0	0	0	0	0	0	0	0
Debt to equity ratio	0.01	0.05	0.15	1.17	0	0.75	0.04	0.04	1.86	0.02	0.01	0.01	0	0	2.54	0.03	0.49	0
Return on equity %	-10.33	-22.71	-86.56	-86.09	0	-107.55	24.48	-33.06	-107.93	-126.60	-114.41	-60.48	-225.08	0	0	-81.83	-121.28	0

Sun Pharma Advanced Research Company Ltd Ratios

The Sun Pharma Advanced Research Company Ltd Ratios page provides a complete fundamental analysis of Sun Pharma Advanced Research Company Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Sun Pharma Advanced Research Company Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Sun Pharma Advanced Research Company Ltd (NSE: SPARC, BSE: 532872) is currently trading at ₹204.22, with a market capitalization of ₹6678.65Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Sun Pharma Advanced Research Company Ltd remains a key stock for fundamental analysis using Sun Pharma Advanced Research Company Ltd Ratios.

Sun Pharma Advanced Research Company Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Sun Pharma Advanced Research Company Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Sun Pharma Advanced Research Company Ltd Ratios.

Historically, the Sun Pharma Advanced Research Company Ltd P/E ratio has shown strong fluctuations:

2024: 0
2023: 0
2022: 0
2021: 0
2020: 0

The decline in Sun Pharma Advanced Research Company Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Sun Pharma Advanced Research Company Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.

Historical P/B trend:

2024: 0
2023: 95.47
2022: 11.36
2021: 258.46

Sun Pharma Advanced Research Company Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Sun Pharma Advanced Research Company Ltd P/S ratio currently stands at 66.92, an important part of Sun Pharma Advanced Research Company Ltd Ratios for revenue valuation.

Historical P/S ratio:

2024: 66.92
2023: 158.92
2022: 21.40
2021: 56.91

A stable or declining Sun Pharma Advanced Research Company Ltd P/S ratio indicates cautious market sentiment.

Sun Pharma Advanced Research Company Ltd Price to Cash Flow Ratio (P/CF)

The Sun Pharma Advanced Research Company Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Sun Pharma Advanced Research Company Ltd Price to Cash Flow Ratio:

2024: 0
2023: 0
2022: 0
2021: 0
2020: 0

The declining Sun Pharma Advanced Research Company Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Sun Pharma Advanced Research Company Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Sun Pharma Advanced Research Company Ltd EV currently stands at ₹5070Cr, representing the total company valuation including debt.

Historical EV trend:

2024: 5070Cr
2023: 11910Cr
2022: 4722Cr
2021: 7878Cr

Sun Pharma Advanced Research Company Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Sun Pharma Advanced Research Company Ltd EV/EBITDA ratio is currently 0, a key metric in Sun Pharma Advanced Research Company Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

2024: 0
2023: 0
2022: 0
2021: 0

Stable Sun Pharma Advanced Research Company Ltd EV/EBITDA indicates balanced valuation.

Sun Pharma Advanced Research Company Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Sun Pharma Advanced Research Company Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

2024: 0
2023: 0.49
2022: 0.03
2021: 2.54

Sun Pharma Advanced Research Company Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Sun Pharma Advanced Research Company Ltd ROE currently stands at 0%, showing profitability and capital efficiency.

Historical ROE:

2024: 0
2023: -121.28
2022: -81.83
2021: 0

Declining ROE indicates pressure on profitability.

Sun Pharma Advanced Research Company Ltd Ratios Analysis Summary

The Sun Pharma Advanced Research Company Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Sun Pharma Advanced Research Company Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Sun Pharma Advanced Research Company Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.